Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Boosts Positions at Investors’ Conference
Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) is yet another almost forgotten ticker that started a new trend in the new year. AMBS gained momentum this week, reaching a successful day on Tuesday with a growth of 33% to $0.1189, on buying volumes of $3.74 million. 
The latest climb for AMBS follows the news that the company has acquired a half-completed drug pathway, paying in cash and stock for eltoprazine from PGI Drug Discovery LLC. The substance is in phase II trials, which AMBS intends to complete as soon as possible. In addition, already at the beginning of 2014 the company started sending out positive messages, such as a blog post by the CEO Gerald Commissiong outlining key developments for the company- one of which would be the intention to uplist to a higher-tier exchange. 
Investors’ forums have mostly caught the optimistic spirit, with the exception of separate opinions that underline the challenge that AMBS faces: to find more funding for a hungry pharmaceutical developer, without issuing too many new shares, causing dilution.
Now, AMBS aims to gain a compensation for licensing one of its main treatments, Lympro, and that would be true material news for the company, which until now has relied on investors’ loyalty and high expectations.
In addition, AMBS will be presenting later this day at the Biotech Showcase in San Francisco. Investors’ conferences are a huge source of new buying for pharma stocks, and usually cause at least a short-term gain, so this ticker may expect a boost through the second half of the week.
AMBS has risen like that in the past, and at 11 cents, it is still cheap enough to allow volatility in either direction. But the months leading up to trials may offer a regular boost to the stock price, by keeping investors active.
In the last few days, pharmaceutical companies on the OTC are more often than not related to medical cannabis. One of the tickers, Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) rose to a penny, growing five times, only to slide back to double-zero levels.
Still others are forgotten, though more solid companies, which are seeing a revival in the new year. Elite Pharmaceuticals, Inc. (OTCBB:ELTP) is on track to double its price since end-December, within reach of the 20-cent levels.
If you still like AMBS, keep in mind that despite the upside, this ticker has shown depressing periods when interest was lost for a while, and a lack of news led to lower volumes. Plan your time frame accordingly, to avoid being caught right into one of the downward periods.
